John Rex is Chief Medical Officer and Director of F2G, LTD, a UK-based antifungal drug discovery and development company.
He is a physician and drug developer with more than 30 years of development and policy experience focused on antimicrobial agents. Throughout his career, he has moved antifungal and antibacterial agents from preclinical development through all development phases. He has held academic positions in the USA at the National Institute of Allergy and Infectious Diseases (NIAID) and the University of Texas Health Science Center at Houston (UTHealth). He also holds a board-level role at Adenium Biotech ApS and is an Expert-in-Residence at Wellcome Trust.
The first 15 years of his career focused on medical mycology and spanned susceptibility testing methods, in vitro-in vivo translational studies, and clinical trials. More recently, he broadened his focus to include advancing novel regulatory and reimbursement paradigms for antimicrobial agents, the founding of the New Drugs for Bad Bugs (ND4BB) programme of Europe’s Innovative Medicines Initiative (IMI), and leadership of an antifungal-focused biotech company.